The world of psychedelic research has taken another significant step forward.
On 7th July 2026, Compass Pathways announced encouraging new data from its second ongoing Phase 3 clinical trial investigating COMP360, a proprietary synthetic formulation of psilocybin, as a treatment for treatment-resistant depression (TRD). While the results are yet to undergo peer review, they represent another important milestone in one of the most advanced clinical programmes investigating psilocybin anywhere in the world.
What is Treatment-Resistant Depression?
Treatment-resistant depression (TRD) affects people whose depression has not improved despite trying multiple conventional treatments.
For many patients, this means living with severe symptoms for years while cycling through different medications and therapies with little success.
Participants enrolled in the COMP006 trial represented a particularly difficult-to-treat group, experiencing depressive episodes lasting, on average, more than three years before entering the study.
What Did the Trial Find?
The Phase 3 COMP006 trial included nearly 600 participants across North America and Europe.
According to Compass Pathways:
• 39% of participants receiving two 25 mg doses of COMP360 experienced a clinically meaningful improvement in depression scores after six weeks.
• Improvements were maintained for at least 26 weeks in many participants.
• Results appeared stronger than those reported in Compass’ earlier Phase 3 COMP005 study, where 25% of participants achieved similar improvements following a single 25 mg dose.
These findings suggest that, for some patients, a second treatment may enhance clinical benefit while maintaining a generally well-tolerated safety profile.
It is important to note that these results come from a company announcement and have not yet been independently peer reviewed.
Why Does This Matter?
Phase 3 clinical trials represent the final major stage of testing before a medicine can be considered for regulatory approval.
Success at this stage means researchers have demonstrated effectiveness and safety in large numbers of patients under carefully controlled conditions.
For psychedelic medicine, reaching this point is a remarkable achievement.
Just a decade ago, modern clinical research into psilocybin was still in its infancy. Today, multiple late-stage clinical trials are investigating its potential for conditions including depression, PTSD and other mental health disorders.
The FDA Approval Path
Compass Pathways has already received several regulatory advantages from the U.S. Food and Drug Administration (FDA).
The company has been granted a rolling New Drug Application (NDA), allowing regulators to review sections of the evidence as they become available rather than waiting for the entire submission.
Compass also received a Commissioner’s National Priority Voucher, designed to accelerate review of promising medicines.
The company expects to complete its NDA submission before the end of 2026, with a potential U.S. launch during the first half of 2027, subject to FDA approval and DEA rescheduling.
A Turning Point for Psychedelic Science
Whether or not COMP360 ultimately receives approval, these latest findings continue a wider trend.
Psychedelic research is moving beyond small proof-of-concept studies into large, rigorous clinical trials capable of informing medical practice.
Every successful study helps expand our scientific understanding of compounds like psilocybin and their potential role in modern mental healthcare.
For researchers, clinicians and those following developments in mycology, these are genuinely exciting times.
As always, we’ll continue following the latest scientific research and bringing you the most important developments from the fascinating world of fungi.
This article is intended for educational purposes only and does not constitute medical advice. Psilocybin treatments discussed remain investigational and are subject to regulatory approval.
